Across TCGA pan-cancer cohorts, ATOH8 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ATOH8 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ATOH8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATOH8 expression acts as an unfavorable survival marker.
BRCA are the cancer types where ATOH8 Mutation most reproducibly stratifies survival.